Severe Hepatic Impairment
9
0
0
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
11.1%
1 terminated out of 9 trials
87.5%
+1.0% vs benchmark
11%
1 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (9)
PK Study in Subjects With Severe Hepatic Impairment
Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
Evaluate Severe Hepatic Impairment on Dacomitinib PK
Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment
A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men